Patients will be eligible for the study if they meet all of the following inclusion
        criteria and none of the exclusion criteria.

        Inclusion criteria

          1. Written informed consent prior to any study-related procedure, and willing and able to
             comply with the protocol and aware of the investigational nature of this study.

          2. At least 18 years of age.

          3. A confirmed GBM diagnosis must be based on local review of tumor tissue from the
             initial biopsy, surgery, or re-resection. A formal pathology report confirming GBM is
             acceptable. It is not a requirement for slides to be sent to a central reviewer.

          4. Recurrent GBM as evaluated by RANO criteria, confirmed by central review, as follows:
             Measurable disease is required with documented unequivocal evidence of tumor
             recurrence or progression following prior therapy (ie, 25% increase in the sum of the
             products of perpendicular diameters of the contrast-enhancing lesions while on stable
             or increasing doses of corticosteroids) as documented by the investigator.

          5. The tumor is localized supratentorially.

          6. The lesion (or sum of lesions) does not exceed 50 cm3 in volume.

          7. MGMT methylation status must be available; results of routinely used methods for MGMT
             methylation testing (eg, methylation-specific polymerase chain reaction or
             quantitative polymerase chain reaction) are acceptable.

          8. No more than 1 prior line of treatment (eg, surgery followed by radiation with
             concomitant chemotherapy, followed by adjuvant chemotherapy is considered as 1 line of
             treatment). A second debulking surgery during the first line treatment is acceptable.
             In addition, treatment with tumor treating fields (TTFields; Optune) is acceptable if
             provided as first line therapy.

          9. Recovery from toxicity/side effects of all prior therapy to Grade 1 or less, subject
             to the investigator's discretion, except for alopecia; the following time intervals
             from previous treatments are required to be eligible:

               1. Twelve weeks from the completion of radiation (to reduce risk of
                  pseudoprogression), unless progression is confirmed by biopsy

               2. 4 weeks from the end of any previous chemotherapy or 6 weeks after the end of
                  treatment with nitrosoureas

               3. 4 weeks from the end of any TTFields treatment

               4. 4 weeks from any major surgery (maximal debulking surgery, either gross total
                  resection or partial resection) or significant traumatic injury, and any surgery
                  incisions or wounds must be completely healed

         10. A stable or decreasing dose of corticosteroids (or none) for brain edema for at least
             5 days prior to baseline MRI and enrollment in the study.

         11. Immunosuppressive therapies allowed include the use of topical, inhalational,
             ophthalmic, or intra-articular glucocorticoids, or the use of physiologic replacement
             doses of glucocorticoids.

         12. Eligible for chemotherapy based on adequate bone marrow function and organ function
             within 2 weeks of study treatment as defined by the following laboratory guidelines,
             subject to the investigator's discretion:

               1. Hematopoietic function: total white blood cell count ≥3000/mm³, absolute
                  neutrophil count ≥1500/mm³, platelet count ≥75,000/mm³, hemoglobin ≥10 g/dL

               2. Hepatic function: bilirubin ≤1.5 × the upper limit of normal (ULN) (excluding
                  Gilberts Syndrome, for which bilirubin must be ≤4 × ULN); aspartate
                  aminotransferase and alanine aminotransferase <3 × ULN, and alkaline phosphatase
                  ≤2.5 × ULN

               3. Renal function: serum creatinine ≤1.5 × ULN or for patients with creatinine
                  levels above the ULN, or estimated creatinine clearance of ≥60 mL/min/1.73 m2,
                  calculated using the Cockcroft-Gault formula

               4. Activated partial thromboplastin time ≤1.5 × ULN

         13. Female patients of childbearing potential, and male study patients and their sexual
             partners of childbearing potential must agree to practice a highly effective method of
             contraception beginning at least 28 days before the start of treatment until at least
             6 months after the last dose of study drug.

               1. A woman of childbearing potential is defined as a woman who is not permanently
                  sterilized or postmenopausal. Postmenopausal is defined as 12 months with no
                  menses without an alternative medical cause.

               2. Women of childbearing potential must have a negative serum or urine pregnancy
                  test.

               3. A highly effective method of birth control is defined as one which results in a
                  low failure rate (ie, less than 1% per year) when used consistently and
                  correctly, such as implants, injectables, combined oral contraceptives, some
                  intrauterine devices, sexual abstinence, or vasectomized partner. For patients
                  using a hormonal contraceptive method, information regarding all medications
                  being administered to the patient and their potential effect on the contraceptive
                  should be addressed.

         14. Patients with prior malignancies must be disease-free for ≥5 years. However,
             curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ
             of the cervix, breast, or bladder; or prostate cancer curatively treated at the time
             of screening is allowed.

        Exclusion Criteria

          1. Unable or not willing to comply with the protocol regulations.

          2. Any additional concurrent radiation therapy or chemotherapy (including but not limited
             to temozolomide) for recurrent or progressive GBM after a first line treatment.

          3. Prior treatment with bevacizumab.

          4. Prior treatment with lomustine.

          5. Screening MRI showing a mass effect defined as significant compression of the
             ventricular system and/or a midline shift (≥10 mm, central MRI review).

          6. Any condition (medical, social, psychological) that would prevent adequate information
             and follow-up, including but not limited to clinically relevant psychiatric disorders,
             legal incapacity, dementia, or altered mental status.

          7. Presence of poorly controlled seizures, defined as occurring despite SOC or requiring
             hospitalization.

          8. Prior anthracycline cumulative dose more than 550 mg/m2.

          9. Heart disease:

               1. LVEF <50%

               2. Unstable angina

               3. Congestive heart failure with New York Heart Association classification of 3 or 4

               4. Patients with baseline QT/QTc interval >480 msec, a history of additional risk
                  factors for torsades de pointes (eg, heart failure, hypokalemia, family history
                  of long QT syndrome) and using concomitant medications that significantly prolong
                  the QT/QTc interval

               5. History of myocardial infarction within 12 months of enrollment

         10. Uncontrolled hypertension (systolic blood pressure [BP] >150 mmHg and/or diastolic BP
             >100 mmHg).

         11. Known to be positive for hepatitis B virus surface antigen (HBsAg), hepatitis C virus
             (HCV), human immunodeficiency virus (HIV), COVID-19 (currently positive at time of
             screening), or any other acute viral, bacterial, or fungal infection (testing not
             required unless symptomatic or suspected disease).

         12. Any other uncontrolled intercurrent medical conditions, including but not limited to
             diabetes mellitus or chronic obstructive pulmonary disease that have not been well
             controlled by medical management over the prior 3 months are ineligible unless
             approved by the sponsor.